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Abstract 
Heterozygous germline mutation of RUNX2 (runt-related protein 2) causes 
cleidocranial dysplasia.  To clarify the involvement of RUNX2 in human osteogenesis, 
fetal bones and various bone tumors were immunohistochemically examined.  During 
both membranous and endochondral ossification in fetus (n=8), RUNX2 was expressed 
not only in osteoblastic cells but also in surrounding mesenchymal cells, and at an early 
stage of chondrocytes.  Such an expression pattern was recapitulated in bone tumors: 
RUNX2 was unequivocally expressed in osteosarcoma (n=20) and fibrous dysplasia 
(n=10), regardless of the site of occurrence, cell morphology or amount of neoplastic 
osteoid. RUNX2 expression was limited to less differentiated cells in chondrogenic 
tumors (n=20).  We further analyzed whether RUNX2 expression was regulated by 
bone morphogenetic protein-2 (BMP-2), which is critical for osteoblastic differentiation.  
By real-time PCR, RUNX2 mRNA level was correlated with BMP-2 mRNA level, and 
both levels were significantly higher in 3 osteosarcoma cell lines than in 3 
chondrosarcoma cell lines.  By treatment with recombinant BMP-2, RUNX2 mRNA 
level was significantly altered in these cell lines.  RUNX2 expression is constitutive in 
developing and neoplastic human osteogenesis, and is most likely to be regulated by 
BMP-2. 
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Introduction 
The skeletal tissue is composed of different mesenchymal cells, including osteoblasts, 
chondrocytes, muscle cells and adipocytes.  These cell lineages are considered to 
differentiate from common mesenchymal progenitor cells, under the control of different 
transcription factors that are specific to differentiation into each lineage.  RUNX2 
(runt-related protein 2), also called Cbfa1 (core binding factor alpha1), is a 
transcriptional factor that belongs to the RUNX family, and is a critical factor in 
osteoblastic differentiation in rodents
1)
.  Mice with a homozygous mutation in Runx2 
showed a complete lack of ossification, including both membranous and endochondral 
ossification
2)
.  In humans, heterozygous germline mutation of RUNX2 causes 
cleidocranial dysplasia, which is characterized by hypoplasia/aplasia of clavicles and 
patent fontanelles
3),4)
. Considering the fact that both clavicles and cranial bones develop 
through membranous ossification, RUNX2 is at least necessary for membranous 
ossification in humans.  However, it is unclear whether RUNX2 is also responsible for 
endochondral ossification in humans.  RUNX2 expression in various bone tumors with 
or without osteoblastic differentiation is not yet systematically analyzed. 
RUNX2 is regulated by several molecules.  Previous studies showed that bone 
morphogenetic protein-2 (BMP-2), which is responsible for both osteoblastic and 
chondroblastic differentiation
5),6)
, regulated RUNX2 expression or function in mouse 
pluripotent mesenchymal cells
7),8)
.  To our knowledge, there are no data on the 
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relationship between BMP-2 and RUNX2 in human osteogenic or chondrogenic cells. 
In the present study, we examined human fetal bones and various bone tumors for 
RUNX2 expression.  Regulation of RUNX2 by BMP-2 was also analyzed using 
human osteosarcoma and chondrosarcoma cell lines. 
 
Materials and methods 
Fetal bones 
Eight fetal tissues were obtained from spontaneous abortion or stillbirth.  Numbers in 
terms of estimated gestational week were as follows: 6 weeks (n=1), 9 weeks (n=1), 10 
weeks (n=1), 11 weeks (n=1), 12 weeks (n=2), 22 weeks (n=1) and 36 weeks (n=1).  
Among the 8 fetal tissues, seven contained limb and vertebral bones, and two (10-week 
and 11-week gestation) contained craniofacial bones (Table 1).  Use of fetal bones was 
approved by the Ethics Committee of Yamagata University School of Medicine.  All 
tissues were fixed in 10% formalin, embedded in paraffin, and sectioned without 
decalcification. 
 
Tumor specimens 
 Tumor specimens are summarized in Table 2.  Bone tumors included osteosarcoma 
(n=20), fibrous dysplasia (n=10), chondrosarcoma (n=10) and enchondroma (n=10), all 
of which were obtained from biopsy.  Cell morphology of osteosarcoma was either 
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osteoblastic or fibroblastic, or both.  Histological grade of chondrosarcoma was grade 
1 (n=4) or grade 2 (n=6).  Sarcomatoid renal cell carcinoma (n=5) and 
leiomyosarcoma of uterus (n=7) were also examined, because they should be 
differentiated from fibroblastic-type osteosarcoma when they metastasize to the bones.  
All of the specimens were fixed in 10% formalin, embedded in paraffin, and sectioned 
without decalcification. 
 
Cells and culture 
Three human osteosarcoma (OS) cell lines, designated as NOS-1, NOS-2 and HuO9, 
and three human chondrosarcoma (CS) cell lines, designated as CRL-7891, HTB-94 and 
OUMS-27, were used.  The NOS-1 and NOS-2 were established by one of the authors 
(T. M.), and the HuO9 was obtained from Japanese Cancer Research Resources Bank 
(Tokyo, Japan).  CRL-7891 (designation: Hs 819.T) and HTB-94 (designation: 
SW1353) were purchased from American Type Culture Collection (Manassas, VA).  
OUMS-27 was kindly donated by Dr. M. Namba (Institute of Molecular and Cellular 
Biology, Okayama University Medical School).  When the cell lines are 
heterotransplanted into nude mice, NOS-1 and HuO9 form bone and osteoid, NOS-2 
forms osteoid and cartilage
9)-11)
, and HTB-94 and OUMS-27 form cartilage
12),13)
.  The 
OS lines were cultured in α-MEM (Cosmo Bio, Tokyo, Japan) supplemented with 10% 
fetal bovine serum (PAA Laboratories, Linz, Austria), and the CS lines were cultured in 
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RPMI-1640 (Nissui Seiyaku, Tokyo, Japan) supplemented with 10% fetal bovine serum.  
All cell lines were incubated in a humidified 5% CO2 atmosphere at 37 °C. 
 
Immunohisto/cytochemistry for RUNX2 
Immunohistochemistry and immunocytochemistry were performed on paraffin 
sections and chamber slides, respectively.  Four-micrometer-thick paraffin sections of 
archival specimens were deparaffinized.  The confluent cells on chamber slides were 
washed with phosphate-buffered saline, and then fixed with 80% ethanol at 4°C for 30 
minutes.  For antigen retrieval, the paraffin sections and chamber slides were 
pretreated with autoclave heating (paraffin sections) at 121°C for 15 minutes and 
microwave heating (chamber slides) at 95°C for 20 minutes in sodium citrate buffer (10 
mM sodium-citrate monohydrate, pH 6.0).  Endogenous peroxidase was inactivated 
with 0.3% hydrogen peroxide for 30 minutes, and the slides were exposed to 3% skim 
milk in phosphate-buffered saline for 20 minutes to block nonspecific binding of the 
antibody.  Then, the slides were incubated with rabbit anti-RUNX2 polyclonal 
antibody (M70; dilution 1/50; Santa Cruz Biotechnology, CA, USA) for 2 hours at room 
temperature.  They were visualized using UltraTech HRP Streptavidin-Biotin 
Detection System (Beckman-Coulter, Marseille, France). 
 
RNA isolation and quantitative real-time PCR analysis 
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Total RNA was extracted from each cell line using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA).  One microgram of total RNA was reverse-transcribed using 
mRNA Selective PCR Kit Ver.1.1 for first-strand cDNA synthesis (TaKaRa, Otsu, 
Japan).  All real-time PCR reactions contained the first-strand cDNA, Power SYBR 
Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and each primer 
mix.  Real-time PCR primers are summarized in Table 3.  The SYBR Green-based 
quantitative real-time PCR analysis was carried out using the Applied Biosystem 7500 
Real-Time PCR System (Applied Biosystems).  The cycling program of RUNX2, 
BMP-2 and GAPDH was as follows: 95 °C × 10 minutes for one cycle, 40 cycles at 
92 °C × 20 seconds, 57 °C × 30 seconds and 72 °C × 40 seconds, followed by a plate 
read at 72 °C for each cycle.  All samples were normalized by the expression level of 
GAPDH.  Triplicate reactions were carried out for each sample.  
 
Treatment with recombinant human BMP-2 
1×105 cells of each cell line were inoculated in 35-mm tissue culture dishes. When 
they reached at 80% confluent state, they were incubated for 72 hours with medium 
containing 500 ng/ml recombinant BMP-2 (R&D Systems, Inc., Minneapolis, USA).  
As a control, culture without recombinant BMP-2 was used. After 72 hours, total RNA 
was obtained from each dish, and RUNX2 mRNA level was evaluated by quantitative 
real-time PCR． 
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Statistical analysis 
The data values are shown as the average of experiments (means ± SD). 
Significance of differences was analyzed using Student’s t-test.  A value of p < 0.05 
was regarded as statistically significant.   
 
Results 
RUNX2 expression in human fetal bones 
In the formation of craniofacial bones, bone matrix was accompanied by osteoblasts 
and osteocytes, but not accompanied by cartilage.  Distinct nuclear expression of 
RUNX2 was observed in osteoblasts, osteocytes, and mesenchymal cells of primitive 
appearance that aggregated around the bone matrix (Fig. 1a,b).   
At the earlier stage (6～11 weeks) of osteogenesis of limb or vertebral bones, 
cartilage was first formed, followed by osteoblastic lining, then bone collar was formed 
between cartilage and osteoblastic layer.  Distinct nuclear expression of RUNX2 was 
observed not only in osteoblastic cells but also in mesenchymal cells that surrounded 
the osteoblastic cells.   Some nuclei of chondrocytes were also positive for RUNX2 
(Fig. 1c).  At the later stage of osteogenesis, the cartilage was invaded by blood vessels, 
then endochondral ossification occurred.  RUNX2 was still expressed by osteoblasts, 
but not expressed by hypertrophic chondrocytes (Fig. 1d). 
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RUNX2 expression in tumor specimens 
RUNX2 expression in tumor specimens is summarized in Table 4.  In each tumor 
type (i.e., osteosarcoma, fibrous dysplasia, chondrosarcoma and enchondroma), all 
cases were positive for RUNX2.  In osteosarcomas, almost all tumor cells showed 
nuclear positivity for RUNX2, regardless of the site of occurrence (limb/pelvic bones or 
jawbones), the amount of osteoid (rich or poor) or the cell morphology (osteoblastic or 
fibroblastic).  In fibrous dysplasia, not only osteoblastic cells rimming the woven 
bones but also fibroblastic cells were positive for RUNX2 in their nuclei, regardless of 
the amount of woven bones or site of occurrence.  On the other hand, chondrosarcoma 
and enchondroma showed heterogeneity in RUNX2 expression: nuclear RUNX2 
staining was found in tumor cells that were small in size and lacked lacunar formation, 
whereas it was rarely found in tumor cells that were hypertrophic or associated with 
lacunae.  Neither sarcomatoid renal cell carcinomas nor uterine leiomyosarcomas 
showed RUNX2 expression (Fig. 2).   
 
RUNX2 and BMP-2 expression in cell lines 
Three OS lines, NOS-1, HuO9 and NOS-2, showed distinct nuclear immunostaining 
for RUNX2.  Among 3 CS lines, CRL-7891 and OUMS-27 were scarcely 
immunostained with RUNX2, and HTB-94 showed weak immunostaining (Fig. 3a). 
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Such in situ expressions were almost concordant with the RUNX2 mRNA level, which 
was significantly higher in OS lines than in CS lines (p<0.0001) (Fig. 3b).  BMP-2 
mRNA level was also significantly higher in OS lines than in CS lines (p<0.0001) (Fig. 
3c).   
 
Effect of BMP-2 on RUNX2 expression 
  After treatment with recombinant BMP-2, RUNX2 mRNA level significantly 
decreased in 3 OS lines, whereas it increased in 3 CS lines (p<0.0001) (Fig. 4).  
 
Discussion 
  The present analysis using human fetus showed that RUNX2 was expressed during 
both membranous and endochondral ossification at all gestational stages examined.  In 
either mode of ossification, RUNX2 was expressed not only in osteoblastic cells but 
also in mesenchymal cells that surrounded the osteoblastic cells.  Such an expression 
pattern was concordant with the in situ expression pattern of RUNX2 mRNA observed 
in membranous ossification
14)
.  Mesenchymal cells that aggregate around the 
osteoblasts are considered to be precursors of osteoblasts, including so-called 
preosteoblasts
15)
, although they have not been specified morphologically.  The present 
finding is compatible with an experimental finding that Runx2 knockout mice did not 
even show aggregation of mesenchymal cells
16),17)
.  As for RUNX2 expression in fetal 
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cartilage, there was a tendency that RUNX2 immunostaining was diminished as the 
chondrocytes became more hypertrophic.  Any products associated with chondrocyte 
maturation might possibly act as repressors of RUNX2.   
  RUNX2 expression in various bone tumors were fairly analogous to that observed in 
fetal skeleton.  In fibrous dysplasia, RUNX2 was strongly expressed not only in 
osteoblasts rimming the woven bones but also in fibroblastic cells, which is concordant 
with a previous finding on RUNX2 expression in fibrous dysplasia of jawbones
18)
.  For 
a long time, it has been presumed that fibroblastic cells of fibrous dysplasia share 
phenotypic features with osteoprogenitor cells.  A previous study showed that 
fibroblastic cells were immunoreactive for osteonectin
19)
.  We consider that the 
RUNX2 immunohistochemistry gives stronger support for this presumption, since 
RUNX2 is a more fundamental molecule in osteogenic differentiation
20)
.  Regarding 
the RUNX2 expression in osteosarcoma, previous studies showed RUNX2 
overexpression by immunohistochemistry or quantification of mRNA
21),22)
.  However, 
they did not refer the site of occurrence or the amount of neoplastic osteoid.  In the 
present study, we showed that RUNX2 was constitutively expressed in osteosarcomas, 
regardless of the affected site (limb/pelvic bones or jawbones).  In every case, almost 
all tumor cells were distinctly positive for RUNX2, even if they showed fibroblastic 
morphology and there was little osteoid.  On the contrary, sarcomatoid renal cell 
carcinomas or uterine leiomyosarcomas, bone metastasis of which is sometimes difficult 
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to distinguish from osteosarcomas
23)
, were completely negative for RUNX2.  RUNX2 
is likely to be helpful to differentiate osteosarcoma from these metastatic tumors.  
Further study in a larger series is necessary to examine whether RUNX2 could be a 
marker of practical use.   
RUNX2 is transcriptionally regulated by various molecules, including fibroblast 
growth factors, TGF-β and BMPs17).  BMP-2 is the most potent osteogenic agents, 
which strongly promotes the differentiation of pluripotent mesenchymal cells into 
osteoblastic cells
5)
, and is also involved in chondrogenic differentiation
6)
.  Previous 
studies using pluripotent mesenchymal cell lines showed that RUNX2 mRNA was 
induced by BMP-2
7)
, or that RUNX2 activity was reduced by blocking BMP-2
8)
.  As 
far as we are aware, there are no data on the relationship between BMP-2 and RUNX2 
expressions in human osteogenic or chondrogenic cells.  In the present study, we 
examined 3 osteosarcoma (OS) cell lines and 3 chondrosarcoma (CS) cell lines in terms 
of the relationship between BMP-2 and RUNX2.  Semi-quantification of intrinsic 
mRNA showed that RUNX2 mRNA level was correlated with BMP-2 mRNA level, 
suggesting that intrinsic BMP-2 positively regulates RUNX2 expression in human 
osteogenic and chondrogenic cells.  To verify this speculation, we treated the 6 cell 
lines with recombinant BMP-2 and analyzed the RUNX2 mRNA level.  In both OS and 
CS lines, significant alteration in RUNX2 mRNA level was found after treatment with 
BMP-2.  The pattern of alteration, however, was different between OS lines and CS 
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lines: RUNX2 mRNA level significantly decreased in OS lines, whereas it increased in 
CS lines.  This indicates that RUNX2 expression is positively regulated by BMP-2 in 
some conditions, but negatively regulated in other conditions, in human osteogenic or 
chondrogenic cells.  It is known that BMP signaling is transduced by the Smad family, 
such as Smad1, Smad4 and Smad5.  They form a complex, move into the nucleus and 
activate target genes
24)
.  It is interesting that the activated genes include Smad6 or 
noggin, the products of which inhibit BMP signaling and thereby preclude cells from 
exhibiting too much BMP signaling
25),26)
.  In the present study, such a negative 
feedback loop might have come into play in the 3 OS lines because they already had a 
significant amount of intrinsic BMP-2.  Systemic studies on the BMP-2 signaling 
pathway are needed to clarify how RUNX2 expression is regulated by BMP-2.   
In summary, RUNX2 is expressed from the early to late stage of osteoblastic 
differentiation during both membranous and endochondral osteogenesis.  RUNX2 is 
also constitutively expressed in osteogenic tumors, regardless of the site of occurrence, 
cell morphology or amount of osteoid.  At the mRNA level, RUNX2 expression is 
most likely to be regulated by BMP-2 in both osteogenic and chondrogenic cells.   
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Table 1.  Fetal bones 
 
Week Membranous ossification Endochondral ossification 
6   limb, vertebral bone 
9 
 
limb, vertebral bone 
10 craniofacial bone 
 
11 craniofacial bone limb, vertebral bone 
12 
 
limb 
12 
 
limb 
22 
 
vertebral bone 
36   vertebral bone 
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Table 2.  Tumor specimens 
 
Tumors No. of cases 
Osteosarcoma 20 
       limb or pelvic bones 16 
       jawbones 4 
Fibrous dysplasia* 10 
Chondrosarcoma* 10 
Enchondroma** 10 
  
Sarcomatoid renal cell carcinoma 5 
Uterine leiomyosarcoma 7 
* Limb or pelvic bones, except for jawbones. 
** Limb bones. 
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Table 3.  Primers for real-time PCR 
Primer Sequence (5' to 3' orientation) 
RUNX2 (F) GACACCACCAGGCCAATC 
RUNX2 (R) AGAACAAGGGGGCCGTTA 
BMP-2 (F) GGGCATCCTCTCCACAAA 
BMP-2 (R) GTCATTCCACCCCACGTC 
GAPDH (F) CAGCGACACCCACTCCTC 
GAPDH (R) TGAGGTCCACCACCCTGT 
F, forward; R, reverse 
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Table 4.  RUNX2 expression of tumor specimens 
Tumors Positive Negative 
Osteosarcoma 20 0 
Fibrous dysplasia 10 0 
Chondrosarcoma 10 0 
Enchondroma 10 0 
   
Sarcomatoid renal cell carcinoma 0 5 
Uterine leiomyosarcoma 0 7 
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Figure legends 
Fig. 1. RUNX2 expression during osteogenesis in human fetus.  a. Longitudinal 
section of a fetus at 11 gestational weeks.  Ossification center appeared in the 
maxillar region (arrowhead), whereas primordia of vertebral column and limbs 
consisted of cartilage.  b. High magnification of the ossification center 
appeared in the maxillar region at 11 gestational weeks.  It was membranous 
ossification without cartilage.  RUNX2 was expressed not only in osteoblasts 
or osteocytes but also in mesenchymal cells that proliferated around the bone 
matrix.  c. High magnification of tibia at 9 gestational weeks (upper) and 
forearm at 11 gestational weeks (lower).  Osteoblastic lining on cartilage and 
subsequent bone collar formation was observed.  RUNX2 was expressed not 
only in osteoblastic cells but also in spindle-shaped mesenchymal cells that 
surrounded the osteoblastic cells.  Some chondrocytes were also 
immunoreactive with RUNX2.  d. Endochondral ossification in vertebral bone 
of a fetus at 22 (upper) and 36 (lower) gestational weeks.  Osteoblasts that lined 
the bone trabeculae showed distinct RUNX2 expression.  Hypertrophic 
chondrocytes rarely showed RUNX2 expression (a, hematoxylin and eosin.  
b-d, left, hematoxylin and eosin; right, immunostaining for RUNX2. ). 
 
Fig. 2. RUNX2 expression in tumor specimens.  In osteosarcomas, tumor cells of 
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both osteoblastic and fibroblastic morphology showed distinct RUNX2 
expression, even in the area where osteoid was inconspicuous.  Reactive 
osteoclast-like cells (arrows) were negative for RUNX2.  RUNX2 
expression was also found in both fibroblastic cells and osteoblastic cells that 
rimmed the woven bones of fibrous dysplasia.  In chondrosarcoma and 
enchondroma, small-sized cells showed RUNX2 immunostaining, whereas 
differentiated cells with lacunae showed scarce immunostaining.  
Sarcomatoid renal cell carcinoma and uterine leiomyosarcoma, bone 
metastasis of which should be differentiated from osteosarcoma, was 
completely negative for RUNX2 (upper, hematoxylin and eosin stain; lower, 
immunostaining for RUNX2.). 
 
Fig. 3. a. Immunocytochemistry for RUNX2 in osteosarcoma (OS) lines (NOS-1, HuO9, 
NOS-2) and chondrosarcoma (CS) lines (CRL-7891, HTB-94, OUMS-27).   
The three OS lines showed distinct RUNX2 immunostaining.  Two of the 3 
CS lines (CRL-7891 and OUMS-27) did not show significant 
immunostaining for RUNX2, and HTB-94 showed faint immunostaining 
(immunostaining for RUNX2). 
      b. RUNX2 mRNA level in 6 cell lines.  It was significantly higher in OS lines 
(NOS-1, HuO9, NOS-2) than in CS lines (CRL-7891, HTB-94, OUMS-27) 
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(*p<0.0001). 
      c. BMP-2 mRNA level in 6 cell lines.  Like the RUNX2 mRNA level, this was 
significantly higher in OS lines than in CS lines (*p<0.0001). 
 
Fig. 4. Alteration of RUNX2 mRNA level following BMP-2 treatment of osteosarcoma 
cell lines (NOS-1, HuO9, NOS-2) and chondrosarcoma cell lines (CRL-7891, 
HTB-94, OUMS-27).  All 6 cell lines were treated with recombinant BMP-2 
(500 ng/ml) for 72 hours.  After treatment, RUNX2 mRNA level significantly 
decreased in the 3 osteosarcoma cell lines, whereas it increased in the 3 
chondrosarcoma cell lines (*p<0.0001). 
 
